|
| Meet the Team |
|
| |
|
|
Richard Lebovitz, Chief Executive Officer
Richard Lebovitz is a co-founder of Abingdon Life Sciences and brings over twenty years of leadership experience. His most recent position was as an executive with Computer Sciences Corporation (CSC) where he led the company’s U.S. systems engineering organization and portions of the restructuring of the business to a global model. Previously at CSC, Mr. Lebovitz held positions as Director of Distributed Systems Engineering, and Senior Consultant in CSC’s ERP practice. Prior appointments include Manager of Application Systems at Amylin Pharmaceuticals, and as a consultant to Isis Pharmaceuticals and Sharp Healthcare. Richard holds a Bachelor of Science degree in Computer Science from Skidmore College, and an MBA from the Wharton School of Business at the University of Pennsylvania. |
 |
|
|
|
 |
|
Aidan Nuttall, President and Chief Operating Officer
Aidan Nuttall is a co-founder of ALSCorp and has over 30 years experience in the pharmaceutical industry. His most recent appointment was President, Chiltern US where he is credited with leading an increase in sales and revenue by threefold in a five year period and increasing the overall size of Chiltern’s US business. He also served as a member of Chiltern’s Executive Board. Prior to this, he was Senior Director, Clinical Development, at Maxim Pharmaceuticals where he led the NDA team for Ceplene™ before becoming Senior Director, Product Development (Anti-infectives). In other previous appointments, Aidan was Director, Clinical Development for Amylin Pharmaceuticals (EU) where he built and led the Clinical Development department. Prior to moving to Amylin, Aidan had been involved in cardiovascular research with Astra-Zeneca Pharmaceuticals. He has a Bsc in Applied Biology, an MSc in Cardiovascular Pathology and a PhD in the role of immunology in the treatment of cancer.
|
|
|
|
 |
|
Janet Peterson-Nuttall, Vice President Clinical Development
Janet Peterson-Nuttall has extensive experience in successful global and business management with biotech and pharma companies. She has been an integral member of several NDA submission teams. Janet has considerable experience with oncology studies and her previous role was as an independent consultant for business and clinical operations, particularly in the field of oncology. Her prior position was Senior Director, Clinical Operations, La Jolla Pharmaceuticals Inc, where her responsibilities included global management of the company’s clinical operations for phase III studies including in-house management and management of CROs. Prior positions include Director, Clinical Operations, Valeant Pharmaceuticals and Director, Clinical Development, Maxim Pharmaceuticals where she was involved in the submission of an NDA and preparation of an MAA. Janet holds a BS in Public Health and an MPH degree and is nursing qualified. |
|
|
|
 |
|
Mark Sarno, Vice President Scientific Affairs
Mark Sarno has over 25 years experience in research, development, clinical/regulatory, biostatistics, and project management within the pharmaceutical, in vitro diagnostics, and medical device fields. He has commercialized 29 products covering such diverse clinical areas as oncology, cardiovascular disease, infectious diseases, metabolic diseases, rheumatology, and gastroenterology. He is a patented inventor and currently has several patent applications in process. He founded Vision Biotechnology Consulting, which for 12 years assisted companies in design, development, clinical research, and regulatory affairs resulting in multiple FDA clearances and approvals. He was also previously Director of Product Development, at NovaDx Inc., which developed the first specific in vitro diagnostic test for rheumatoid arthritis and osteoarthritis. As a biostatistician, Mr. Sarno has analyzed some of the seminal epidemiological studies in cardiovascular disease including the Atherosclerosis Risk in Communities (ARIC) study. Mr. Sarno holds a BA in Biochemistry and Cell Biology from the University of California at San Diego. |
|
|
|
 |
|
Charles H. Davis, RAC, Vice President, Regulatory Affiars
Mr. Davis is an experienced regulatory professional with 37 years of experience in pharmaceutical industry regulatory affairs and quality assurance functions and 7 years in clinical research management. He is experienced in the complete process of drug development from concept through preclinical development, IND submission, clinical trials, and NDA/MAA submission and approval, as well as product life cycle management. Mr. Davis has brought both drug and biologic products to commercial launch in the fields of cardiac imaging; coronary angioplasty; gastroenterology; parenteral nutrition; ophthalmology; and contraception. He has organized and led the sponsor teams in several pre-approval (PAI) GMP inspections, sponsor/monitor clinical study inspections and other bioresearch monitoring inspections by FDA and other regulatory agencies. Prior to joining Abingdon Life Sciences Mr. Davis was Senior Director, Regulatory Affairs at Santarus, Inc. In other previous appointments Mr. Davis held executive or senior regulatory/quality assurance positions at Prometheus Laboratories, Arena Pharmaceuticals, Maxim Pharmaceuticals, Sonus Pharmaceuticals, Alpha Therapeutic Corp. and ALZA Corp. At Sonus Mr. Davis also managed the clinical research and biostatistics functions. Mr. Davis has established successful working relationships with FDA reviewers in several CDER Divisions and the Office of Generic Drugs and has been responsible for planning and execution of numerous face-to-face meetings with FDA and its Advisory Committees and other agencies, including EMEA, Health Canada, MHRA (UK), Medicines Evaluation Board (Netherlands), AFSSAPS (France), and the Therapeutic Goods Administration (Australia). Mr. Davis holds 2 US patents, is a certified regulatory professional (RAC), and holds a BS in Organic Chemistry from the University of California, Berkeley.
|
|
|
|
